Login to Your Account

China's Generon receives U.S. FDA SPA for pivotal trial of G-CSF candidate

By David Ho
Staff Writer

Tuesday, October 17, 2017

HONG KONG – Generon Corp. (Shanghai) Ltd. has reached an agreement with the FDA under a special protocol assessment (SPA) regarding the second pivotal global phase III study design of its chemotherapy-induced neutropenia (CIN) treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription